322 related articles for article (PubMed ID: 27884092)
61. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
62. Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era.
Nagle SJ; Woo K; Schuster SJ; Nasta SD; Stadtmauer E; Mick R; Svoboda J
Am J Hematol; 2013 Oct; 88(10):890-4. PubMed ID: 23813874
[TBL] [Abstract][Full Text] [Related]
63. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.
Shin HJ; Chung JS; Song MK; Kim SK; Choe S; Cho GJ
Cancer Chemother Pharmacol; 2012 May; 69(5):1165-72. PubMed ID: 22215473
[TBL] [Abstract][Full Text] [Related]
64. How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience.
Huang BT; Zeng QC; Yu J; Xiao Z; Li BS; Zhang CL; Ji HB
J Cancer Res Clin Oncol; 2012 Jan; 138(1):125-32. PubMed ID: 22057732
[TBL] [Abstract][Full Text] [Related]
65. The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase.
Kim YR; Kim SJ; Cheong JW; Yang DH; Lee H; Eom HS; Sung YO; Kim HJ; Kang HJ; Lee WS; Park Y; Yang WI; Min YH; Kim JS
Ann Hematol; 2016 Sep; 95(9):1491-501. PubMed ID: 27324387
[TBL] [Abstract][Full Text] [Related]
66. The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma.
Nagle SJ; Chong EA; Chekol S; Shah NN; Nasta SD; Glatstein E; Plastaras JP; Torigian DA; Schuster SJ; Svoboda J
Cancer Med; 2015 Jan; 4(1):7-15. PubMed ID: 25205600
[TBL] [Abstract][Full Text] [Related]
67. Rituximab as consolidation therapy did not improve outcome in patients with diffuse large B-cell lymphoma at complete response after dose-dense chemotherapy (CHOP-14).
Avilès A; Nambo MJ; Huerta-Guzmàn J; Silva L; Neri N
Cancer Biother Radiopharm; 2015 Apr; 30(3):107-10. PubMed ID: 25871407
[TBL] [Abstract][Full Text] [Related]
68. Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase II study (JSCT-NHL04).
Murayama T; Fukuda T; Okumura H; Sunami K; Sawazaki A; Maeda Y; Tsurumi H; Uike N; Hidaka T; Takatsuka Y; Eto T; Tsuda H; Fujisaki T; Miyamoto T; Tsuneyoshi N; Iyama S; Nagafuji K; Harada M
Int J Hematol; 2016 Jun; 103(6):676-85. PubMed ID: 27084252
[TBL] [Abstract][Full Text] [Related]
69. Long-term complete remission following tandem autologous stem cell transplantation and consolidative radiotherapy for refractory mediastinal gray-zone lymphoma.
Takaishi K; Muto T; Mimura N; Takiguchi J; Nagao Y; Oshima-Hasegawa N; Tsukamoto S; Takeda Y; Mitsukawa S; Takeuchi M; Ohwada C; Ota S; Iseki T; Nakaseko C; Sakaida E
Int J Hematol; 2018 Oct; 108(4):452-455. PubMed ID: 29786758
[TBL] [Abstract][Full Text] [Related]
70. [Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients].
Qin Y; Shi YK; He XH; Han XH; Zhou SY; Liu P; Yang JL; Yang S; Zhang CG; Dong M; Zhou LQ; Wang JW; Feng FY; Sun Y
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):469-73. PubMed ID: 19950562
[TBL] [Abstract][Full Text] [Related]
71. A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma.
Armand P; Redd R; Bsat J; Mayuram S; Giardino A; Fisher DC; LaCasce AS; Jacobson C; Davids MS; Brown JR; Weng L; Wilkins J; Faham M; Freedman AS; Joyce R; Jacobsen ED
Br J Haematol; 2016 Apr; 173(1):89-95. PubMed ID: 26729345
[TBL] [Abstract][Full Text] [Related]
72. Statin use has negative clinical impact on non-germinal center in patients with diffuse large B cell lymphoma in rituximab era.
Song MK; Chung JS; Lee GW; Cho SH; Hong J; Shin DY; Shin HJ
Leuk Res; 2015 Feb; 39(2):211-5. PubMed ID: 25541029
[TBL] [Abstract][Full Text] [Related]
73. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
74. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
75. Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: A single-centre experience.
Han X; Zhang W; Zhou D; Ruan J; Duan M; Zhu T; Li J; Cai H; Cao X; Ouyang M
J Int Med Res; 2017 Feb; 45(1):290-302. PubMed ID: 28222648
[TBL] [Abstract][Full Text] [Related]
76. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.
Dreyling M; Lenz G; Hoster E; Van Hoof A; Gisselbrecht C; Schmits R; Metzner B; Truemper L; Reiser M; Steinhauer H; Boiron JM; Boogaerts MA; Aldaoud A; Silingardi V; Kluin-Nelemans HC; Hasford J; Parwaresch R; Unterhalt M; Hiddemann W
Blood; 2005 Apr; 105(7):2677-84. PubMed ID: 15591112
[TBL] [Abstract][Full Text] [Related]
77. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
Qiao W; Zhao J; Wang C; Wang T; Xing Y
Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
[TBL] [Abstract][Full Text] [Related]
78. Mediastinal Gray Zone Lymphoma with Features Intermediate between Classical Hodgkin Lymphoma and Primary Mediastinal B-Cell Lymphoma.
Song HN; Kim SJ; Ko YH; Kim WS
Acta Haematol; 2016; 136(3):186-90. PubMed ID: 27623181
[TBL] [Abstract][Full Text] [Related]
79. TP53 mutation and survival in aggressive B cell lymphoma.
Zenz T; Kreuz M; Fuge M; Klapper W; Horn H; Staiger AM; Winter D; Helfrich H; Huellein J; Hansmann ML; Stein H; Feller A; Möller P; Schmitz N; Trümper L; Loeffler M; Siebert R; Rosenwald A; Ott G; Pfreundschuh M; Stilgenbauer S;
Int J Cancer; 2017 Oct; 141(7):1381-1388. PubMed ID: 28614910
[TBL] [Abstract][Full Text] [Related]
80. Rituximab-PECC induction followed by
Lugtenburg PJ; Zijlstra JM; Doorduijn JK; Böhmer LH; Hoogendoorn M; Berenschot HW; Beeker A; van der Burg-de Graauw NC; Schouten HC; Bilgin YM; Kersten MJ; Koene HR; Herbers AHE; de Jong D; Hijmering N; Lam KH; Chiţu D; Brouwer RE; van Imhoff GW;
Br J Haematol; 2019 Nov; 187(3):347-355. PubMed ID: 31290569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]